42307 Matching-adjusted indirect comparison of efficacy of ixekizumab versus secukinumab through 1 year in pediatric patients with severe plaque psoriasis

Background: Ixekizumab (IXE) and secukinumab (SEC) have both shown superiority versus placebo (PBO) and etanercept in clinical trials of pediatric patients with severe psoriasis.